CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $)	Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2010	$ 0	$ 64,382	$ 57,888,506	$ (25,000)	$ (51,827,360)	$ 6,100,528
Balance (in shares) at Dec. 31, 2010	0	64,381,910
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee share-based compensation expense	0	0	1,307,869	0	0	1,307,869
Employee share-based compensation expense (in shares)	0	0
Other share-based compensation expense	0	0	351,214	0	0	351,214
Other share-based compensation expense (in shares)	0	0
Exercise of stock options	0	490	295,263	0	0	295,753
Exercise of stock options (in shares)	0	490,000				490,000
Sale of common stock and warrants (net of $47,333 of offering costs)	0	3,779	3,726,808	0	0	3,730,587
Sale of common stock and warrants (net of $47,333 of offering costs) (in shares)	0	3,778,321
Shares issued in conjunction with conversion of convertible debt	0	406	406,257	0	0	406,663
Shares issued in conjunction with conversion of convertible debt (in shares)	0	406,664
Shares issued in conjunction with acquisition of Surgical Biologics, LLC	0	5,250	7,082,250	0	0	7,087,500
Shares issued in conjunction with acquisition of Surgical Biologics, LLC (in shares)	0	5,250,000
Beneficial conversion feature recognized on convertible debt	0	0	2,715,552	0	0	2,715,552
Warrants issued in conjunction with convertible promissory notes	0	0	14,885	0	0	14,885
Common stock issued for earn-out liability						0
Discount on beneficial conversion feature recognized on line of credit with related party	0	0	80,000	0	0	80,000
Net loss for the period	0	0	0	0	(10,193,986)	(10,193,986)
Balance at Dec. 31, 2011	0	74,307	73,868,604	(25,000)	(62,021,346)	11,896,565
Balance (in shares) at Dec. 31, 2011	0	74,306,895
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee share-based compensation expense	0	0	2,075,680	0	0	2,075,680
Employee share-based compensation expense (in shares)	0	0
Other share-based compensation expense	0	0	463,041	0	0	463,041
Other share-based compensation expense (in shares)	0	0
Exercise of stock options	0	844	1,051,824	0	0	1,052,668
Exercise of stock options (in shares)	0	843,863				843,862
Exercise of warrants	0	7,960	5,993,103	0	0	6,001,063
Exercise of warrants (in shares)	0	7,959,767
Repurchase of warrants	0	0	(568)	0	0	(568)
Repurchase of warrants (in shares)	0	0
Cashless exercise of warrants	0	216	(216)	0	0	0
Cashless exercise of warrants (in shares)	0	216,085
Common stock issued for accrued director fees	0	167	184,486	0	0	184,653
Common stock issued for accrued director fees (in shares)	0	167,086				167,086
Common stock issued for earn-out liability	0	2,632	3,182,591	0	0	3,185,223
Common stock issued for earn-out liability (in shares)	0	2,632,576				2,632,576
Discount on beneficial conversion feature recognized on line of credit with related party	0	0	514,456	0	0	514,456
Common stock issued for acquisition note	0	893	892,374	0	0	893,267
Common stock issued for acquisition note (in shares)	0	893,267
Convertible line of credit with related party		1,404	1,402,226			1,403,630
Convertible of line of credit with related party (in shares)		1,403,630				1,403,630
Net loss for the period	0	0	0	0	(7,662,376)	(7,662,376)
Balance at Dec. 31, 2012	$ 0	$ 88,423	$ 89,627,602	$ (25,000)	$ (69,683,722)	$ 20,007,302
Balance (in shares) at Dec. 31, 2012	0	88,423,169